Reports
Sale
Dyspepsia Market Size, Share, Trends, Growth, Report: By Diagnosis: Blood Tests, Stool Tests, Breath Tests, Endoscopy, Others; By Type: Organic Dyspepsia, Non-Ulcer Dyspepsia, Drug Induced Dyspepsia, Others; By Indication; By Treatment; By Drug Type; By Route of Administration; Regional Analysis; Supplier Landscape; 2024-2032
Dyspepsia Market Outlook
The dyspepsia market size was valued at USD 1102.4 million in 2023, driven by the rising advancements in medical research and development activities across the 7 major markets. The market is expected to grow at a CAGR of 8.4% during the forecast period of 2024-2032, with the values likely to rise from USD 1192.5 million in 2024 to USD 2268.8 million by 2032.
Dyspepsia: Introduction
Dyspepsia, also known as indigestion, is characterized by stomach pain, bloating, and fullness during or after eating. Other symptoms include heartburn, acid reflux, and excessive burping. There are different categories of functional dyspepsia, which involve epigastric pain syndrome as well as postprandial distress syndrome. It may be caused by food allergies, visceral hypersensitivity, and H. pylori infection.
Dyspepsia Market Analysis
The market growth is driven by the high prevalence of the disease worldwide. The incidence is particularly higher in the western countries, affecting 10% to 40% of the population, while the Asian countries have a prevalence rate of 5% to 30%. Diagnostic tests play a pivot role in offering early treatment, hence, upper endoscopy, breath tests and gastric emptying studies are also used for precise diagnosis.
The increased availability of treatment and drugs in the market are also aiding the dyspepsia market growth. Dyspepsia is treated via medication that works to reduce acid production and block acid pumps. Others may include antibiotics to fight against H. pylori bacteria and prokinetics that tighten the valves between stomach and esophagus, helping in abdominal pain reduction.
Apart from pharmacological interventions, herbal and traditional medicinal approaches are another area of interest amongst researchers. Herbals such as peppermint, caraway oil, and turmeric are heavily investigated and have displayed positive results in patients when compared to regular placebos. This is also indicative of the general market trend of adopting wellness and natural products in combination with pharmaceuticals for disease treatments.
Dyspepsia Market Segmentation
Market Breakup by Diagnosis
- Blood Tests
- Stool Tests
- Breath Tests
- Endoscopy
- X-Ray
- CT Scan
- Others
Market Breakup by Type
- Organic Dyspepsia
- Non-Ulcer Dyspepsia
- Drug Induced Dyspepsia
- Others
Market Breakup by Indication
- Functional Dyspepsia
- Organic Dyspepsia
Market Breakup by Treatment
- Proton Pump Inhibitors
- H2 Blockers
- Antacids
- Antibiotics
- Prokinetics
- Antidepressants
Market Breakup by Treatment
- Medication
- Surgery
Market Breakup by Drug Type
- Branded
- Generic
Market Breakup by Route of Administration
- Oral
- Injectable
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
Dyspepsia Market Overview
In the forecast period, the United States is expected to lead the dyspepsia market share. With proactive healthcare and research institutions, there is a heavy emphasis on educating the masses about the condition through early diagnosis and appropriate treatment. In addition, the booming pharmaceutical sector is working on bringing in effective and innovative solutions for patients.
Europe is another major player in the market with a robust healthcare infrastructure, along with rising collaborations between academic and research organizations to develop alternative therapeutics for people. The substantial portion of geriatric population pertaining to the region is another key aspect of the considerable market share of the condition.
The dyspepsia market value is projected to grow with the increasing utility of naturopathy and rising adoption of traditional eastern medicine alternatives for treating the condition. Moreover, the region is witnessing impressive improvements in the medical and research infrastructure which is fostering market growth. Increased influx of foreign capital is another major factor.
Dyspepsia Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Bayer AG
- Mankind Pharma
- Cadila Pharmaceuticals
- Salix Pharmaceuticals
- Sanofi
- Aosaikand Pharmaceutical Co., Ltd
- Hanmi Pharm. Co.
- Lupin
- RedHill Biopharma Ltd.
- Abbott.
- GlaxoSmithKline
- Johnson&Johnson
- Eisai Co Ltd
- AstraZeneca
- Allergen Plc
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Diagnosis |
|
|
Breakup by Type |
|
| Breakup by Indication |
|
| Breakup by Treatment |
|
| Breakup by Treatment Type |
|
| Breakup by Drug Type |
|
| Breakup by Route of Administration |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Dyspepsia Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Drug
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Dyspepsia Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Dyspepsia Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Dyspepsia Epidemiology Forecast (2017-2032)
5.3.1 Germany Dyspepsia Epidemiology Forecast (2017-2032)
5.3.2 France Dyspepsia Epidemiology Forecast (2017-2032)
5.3.3 Italy Dyspepsia Epidemiology Forecast (2017-2032)
5.3.4 Spain Dyspepsia Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Dyspepsia Epidemiology Forecast (2017-2032)
5.4 Japan Dyspepsia Epidemiology Forecast (2017-2032)
6 Dyspepsia Market Overview – 7MM
6.1 Dyspepsia Market Historical Value (2017-2023)
6.2 Dyspepsia Market Forecast Value (2024-2032)
7 Dyspepsia Market Landscape – 7MM
7.1 Dyspepsia: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Dyspepsia Product Landscape
7.2.1 Analysis by Indication
7.2.2 Analysis by Drug Type
8 Dyspepsia Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Dyspepsia Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Dyspepsia Market Segmentation – 7MM
11.1 Dyspepsia Market by Diagnosis
11.1.1 Market Overview
11.1.2 Blood Tests
11.1.3 Stool Tests
11.1.4 Breath Tests
11.1.5 Endoscopy
11.1.6 X-Ray
11.1.7 CT Scan
11.1.8 Others
11.2 Dyspepsia Market by Type
11.2.1 Market Overview
11.2.2 Organic Dyspepsia
11.2.3 Non-Ulcer Dyspepsia
11.2.4 Drug Induced Dyspepsia
11.2.5 Others
11.3 Dyspepsia Market by Indication
11.3.1 Market Overview
11.3.2 Functional Dyspepsia
11.3.3 Organic Dyspepsia
11.4 Dyspepsia Market by Treatment
11.4.1 Market Overview
11.4.2 Proton Pump Inhibitors
11.4.3 H2 Blockers
11.4.4 Antacids
11.4.5 Antibiotics
11.4.6 Prokinetics
11.4.7 Antidepressants
11.5 Dyspepsia Market by Treatment Type
11.5.1 Market Overview
11.5.2 Medication
11.5.3 Surgery
11.6 Dyspepsia Market by Drug Type
11.6.1 Market Overview
11.6.2 Branded
11.6.3 Generic
11.7 Dyspepsia Market by Route of Administration
11.7.1 Market Overview
11.7.2 Oral
11.7.3 Injectable
11.8 Dyspepsia Market by Region
11.8.1 Market Overview
11.8.2 United States
11.8.3 EU-4 and the United Kingdom
11.8.3.1 Germany
11.8.3.2 France
11.8.3.3 Italy
11.8.3.4 Spain
11.8.3.5 United Kingdom
11.8.4 Japan
12 United States Dyspepsia Market
12.1 Dyspepsia Market Historical Value (2017-2023)
12.2 Dyspepsia Market Forecast Value (2024-2032)
12.3 Dyspepsia Market by Diagnosis
12.4 Dyspepsia Market by Indication
13 EU-4 and United Kingdom Dyspepsia Market
13.1 Dyspepsia Market Historical Value (2017-2023)
13.2 Dyspepsia Market Forecast Value (2024-2032)
13.3 Germany Dyspepsia Market Overview
13.3.1 Dyspepsia Market by Diagnosis
13.3.2 Dyspepsia Market by Indication
13.4 France Dyspepsia Market Overview
13.4.1 Dyspepsia Market by Diagnosis
13.4.2 Dyspepsia Market by Indication
13.5 Italy Dyspepsia Market Overview
13.5.1 Dyspepsia Market by Diagnosis
13.5.2 Dyspepsia Market by Indication
13.6 Spain Dyspepsia Market Overview
13.6.1 Dyspepsia Market by Diagnosis
13.6.2 Dyspepsia Market by Indication
13.7 United Kingdom Dyspepsia Market Overview
13.7.1 Dyspepsia Market by Diagnosis
13.7.2 Dyspepsia Market by Indication
14 Japan Dyspepsia Market
14.1 Dyspepsia Market Historical Value (2017-2023)
14.2 Dyspepsia Market Forecast Value (2024-2032)
14.3 Dyspepsia Market by Diagnosis
14.4 Dyspepsia Market by Indication
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 JAPAN PMDA
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnerships and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 Bayer AG
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 Mankind Pharma
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 Cadila Pharmaceuticals
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 Salix Pharmaceuticals
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 Sanofi
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 Aosaikand Pharmaceutical Co., Ltd
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 Hanmi Pharm. Co.
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 Lupin
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 RedHill Biopharma Ltd.
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 Abbott.
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
21.11 GlaxoSmithKline
21.11.1 Financial Analysis
21.11.2 Product Portfolio
21.11.3 Demographic Reach and Achievements
21.11.4 Mergers and Acquisitions
21.11.5 Certifications
21.12 Johnson & Johnson
21.12.1 Financial Analysis
21.12.2 Product Portfolio
21.12.3 Demographic Reach and Achievements
21.12.4 Mergers and Acquisitions
21.12.5 Certifications
21.13 Eisai Co Ltd
21.13.1 Financial Analysis
21.13.2 Product Portfolio
21.13.3 Demographic Reach and Achievements
21.13.4 Mergers and Acquisitions
21.13.5 Certifications
21.14 AstraZeneca
21.14.1 Financial Analysis
21.14.2 Product Portfolio
21.14.3 Demographic Reach and Achievements
21.14.4 Mergers and Acquisitions
21.14.5 Certifications
21.15 Allergen Plc
21.15.1 Financial Analysis
21.15.2 Product Portfolio
21.15.3 Demographic Reach and Achievements
21.15.4 Mergers and Acquisitions
21.15.5 Certifications
22 Dyspepsia Market- Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 1102.4 million in 2023, driven by increasing advancements in medical research and development activities across the major markets.
The market is anticipated to grow at a CAGR of 8.4% during the forecast period of 2024-2032, likely to reach a market value of USD 2268.8 million by 2032.
The market demand is majorly driven by the rising prevalence of unhealthy eating habits and increasing incidence of dyspepsia, especially in the Western countries.
The current market trend involves the application of non-pharmacological, herbal, and natural interventions to treat dyspepsia. As per recent studies, peppermint, caraway oil and turmeric have shown promising results in treatment.
The diagnosis can be divided into blood tests, stool tests, breath tests, endoscopy, X-ray, and CT scan, among others.
Based on product type, the market is divided into organic dyspepsia, non-ulcer dyspepsia, and drug induced dyspepsia, among others.
Treatment type includes proton pump inhibitors, H2 blockers, antacids, antibiotics, prokinetics, and antidepressants.
The route of administration can be oral and injectables.
Branded and generic are common drug types available in the market.
The major regions of the market include the United States, Japan, EU-4 which is segmented into Germany, France, Italy, Spain, and the United Kingdom.
Key players involved in the market are Bayer AG, Mankind Pharma, Cadila Pharmaceuticals, Salix Pharmaceuticals, Sanofi, Aosaikand Pharmaceutical Co., Ltd., Hanmi Pharm. Co., Lupin, RedHill Biopharma Ltd., Abbott., GlaxoSmithKline, Johnson&Johnson, Eisai Co Ltd., AstraZeneca, and Allergen Plc.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER